National Guidelines For The Management Of Cardiovascular Diseases

Objectives

The Ghana cardiovascular disease guideline supports national development by reducing the incidence of chronic non-communicable diseases, unhealthy lifestyles, associated morbidity and effects on quality of life.[1][2]It responds to the high burden of cardiovascular disease in Ghana and other low- and middle-income countries, and to the absence of previously standardised national guidance for cardiovascular disease management.[2]Its overarching clinical purpose is to enable earlier detection, appropriate treatment, capacity building and streamlined referral, thereby reducing cardiovascular morbidity and mortality.[3][2]

• Standardise cardiovascular risk assessment, prevention and management through nationally approved, evidence-based guidance applicable across levels of care.[3][4]
• Prioritise early detection and control of modifiable risk factors, including hypertension, diabetes, dyslipidaemia, obesity, tobacco use, harmful alcohol consumption, unhealthy diet, physical inactivity and obstructive sleep apnoea.[5][6]
• Apply the World Health Organization and International Society of Hypertension risk prediction chart for Africa zone D to estimate 10-year risk of stroke or heart attack and guide risk-based treatment in Ghana.[7]
• Promote lifestyle modification, including culturally appropriate healthy eating, stress management, weight control, physical activity, reduced salt and alcohol intake, and smoking cessation.[8][6][9]
• Address the guideline’s priority clinical areas: risk assessment; cardiac arrest; hypertension; stroke; coronary artery disease and myocardial infarction; heart failure; venous thromboembolism; acute rheumatic fever and rheumatic heart disease; infective endocarditis; and cardiac arrhythmias.[4]
• Strengthen primary and secondary prevention by setting clinical targets for blood pressure, glycaemic control, lipids, physical activity, diet and tobacco avoidance, while treating established atherosclerotic cardiovascular disease as high risk.[6][7]
• Improve emergency outcomes through prompt recognition and management of cardiac arrest, hypertensive emergencies, acute stroke, acute coronary syndrome, pulmonary embolism and life-threatening arrhythmias.[10][11][12][13][14][15]

Implementation

The guideline uses a tiered clinical delivery model, matching assessment, treatment, investigation and referral to facility capacity, from facilities without a doctor to doctor-led facilities, physician or family physician specialist services, and cardiology centres with sophisticated equipment.[3][4]It combines risk-based prevention, standardised clinical protocols, patient education, emergency stabilisation, escalating referral and specialist care for complex conditions.[4][7][16]Development involved the Ministry of Health, Ghana Health Service, the Non-Communicable Disease Control Programme, academic and teaching institutions, professional bodies, the Ghana Heart Initiative and other stakeholders, followed by stakeholder review and Ministry of Health approval for national use.[17][18][2]

• Equip primary healthcare facilities with the technologies, tools, resources and medicines recommended in the World Health Organization technical package for cardiovascular disease management, while distinguishing medicines outside the Essential Medicines List.[4]
• Deliver condition-specific recommendations by level of care, using colour coding to clarify the appropriate service level and referral destination.[4][19][20]
• Assess cardiovascular risk using age, sex, smoking, diabetes, systolic blood pressure and total cholesterol, and use the non-cholesterol risk chart where cholesterol testing is unavailable.[7]
• Engage health workers, patients, families and caregivers in sustained behavioural change through realistic goals, tailored dietary advice, adherence support and education on warning signs and follow-up.[8][21]
• Train pupils, students, commercial drivers, security agencies and health professionals in first aid, basic life support and advanced cardiac life support, including pre-service and continuing professional development.[22]
• Establish emergency response teams in health facilities, equip ambulances and responders appropriately, and aim for emergency-team response within five minutes.[23]
• Stabilise emergencies with cardiopulmonary resuscitation, defibrillation where indicated, oxygen for hypoxaemia, urgent investigations and protocol-led treatment before referral or specialist escalation.[24][25][12][26]
• Refer patients when qualified staff, diagnostic capacity, medicines or specialist support are unavailable, and notify receiving facilities in advance to protect continuity of care.[16][23]
• Use structured Ghana Health Service referral and feedback forms to record clinical findings, investigations, treatment, diagnoses, outcomes, recommendations and review dates, returning feedback to the referring facility.[27]
• Base recommendations on graded evidence, from Level A evidence from multiple randomised clinical trials or meta-analyses to Level C expert consensus or limited studies.[4]

Clinical monitoring is specified for individual conditions, including blood-pressure readings, cardiovascular risk categories, lipid measurements, anticoagulation monitoring, neurological observations and referral thresholds.[28][29][30][12]The guideline does not specify a comprehensive programme-level monitoring framework, routine indicator set, reporting schedule, surveillance system, implementation timetable, accountability mechanism, budget or financing plan.[2][4][17]

Monitoring & Evaluation

The guideline provides extensive clinical monitoring, diagnostic assessment and referral follow-up across cardiovascular conditions, but does not establish a unified programme-level monitoring and evaluation framework, routine reporting system, surveillance architecture, audit cycle, or formal implementation accountability mechanism.[2][4][27]

• Use evidence grading for clinical recommendations, with Level A based on multiple randomised trials or meta-analyses, Level B on a single randomised trial or large non-randomised studies, and Level C on expert consensus or smaller, retrospective or registry studies.[4]
• Apply cardiovascular risk assessment using the World Health Organization/International Society of Hypertension chart for Africa zone D and categorise 10-year risk as below 10%, 10% to 30%, or above 30% to guide prevention and treatment.[7]
• Assess progress against clinical prevention targets for blood pressure, glycaemic control, lipid levels, obesity, physical activity, diet and tobacco exposure.[6]
• Monitor emergency response teams against the expectation that they respond within five minutes, although no wider emergency-care performance framework is specified.[23]
• Standardise hypertension monitoring through repeated office measurements, ambulatory blood-pressure monitoring and home blood-pressure monitoring; reassess treatment response within two to four weeks after initiation or intensification.[28][9][31]
• Monitor acute stroke patients’ blood pressure, pulse, respiratory rate, temperature, blood glucose, neurological status and seizures, while using rapid non-contrast head computed tomography to identify stroke type and guide management.[12][32]
• Use clinical monitoring in cardiac arrest, including level-specific investigations and resuscitation algorithms, but no programme indicators or reporting requirements are specified.[10][24]
• Review lipid-lowering treatment through adherence, lifestyle changes and low-density lipoprotein response, with repeat lipid measurement four to 12 weeks after starting or adjusting statins and every three to 12 months thereafter as needed.[29][33]
• Monitor anticoagulation through International Normalised Ratio testing for warfarin, including defined target ranges and follow-up schedules in venous thromboembolism, rheumatic heart disease and atrial fibrillation care.[30][34][35]
• Use condition-specific clinical follow-up, including daily weighing in severe heart failure, post-discharge review within four weeks after mitral-valve surgery, and clinical and echocardiographic follow-up during the first year after infective endocarditis treatment.[36][37][38][39]
• Document referral and feedback through the Ghana Health Service referral form, recording referral and arrival dates, diagnoses, investigations, treatment, outcomes, responsible officers and signatures; complete feedback forms in duplicate and return them to the referring facility.[27]

Costing & Financing

The guideline identifies substantial clinical resource requirements across levels of care, but does not provide a costed implementation plan, budget allocations, financing sources, resource-mobilisation strategy, quantified funding gap, affordability analysis, or economic assumptions.[4][22][23]

• Provide primary-care facilities with technologies, tools, medicines and other resources recommended in the World Health Organization technical package for cardiovascular disease management.[4]
• Equip facilities according to their care level, from basic diagnostics and medicines in facilities without doctors to telemedicine, cardiac catheterisation, specialist investigations and advanced medicines in specialist services.[22]
• Resource emergency care with trained response teams, paramedics, ambulances, appropriate equipment and medicines, and automated external defibrillators at large institutions.[22][23]
• Recognise that magnetic resonance imaging availability and cost constrain its use in acute stroke care in Ghana.[32]
• Recognise that intravenous thrombolysis and endovascular thrombectomy are not widely available in Ghana, without specifying the financial or supply constraints responsible.[40]
• Recognise that medical complications following stroke increase the cost of care and are associated with longer hospital stays, readmissions, delayed rehabilitation and increased mortality.[41]
• Consider cost as a factor in selecting antiplatelet medicines for stroke secondary prevention, without setting prices, coverage arrangements or eligibility criteria.[42][43]
• Recognise that access and socioeconomic circumstances influence the choice between intensified medical management and invasive acute-coronary-syndrome treatment; maximise medical therapy when fibrinolysis or percutaneous coronary intervention is unaffordable.[44][45]
• Identify resource-intensive requirements, including stroke units, multidisciplinary rehabilitation, advanced imaging, revascularisation, device therapies, cardiac surgery, specialist laboratories and anticoagulation monitoring, but do not assign monetary values or funding responsibilities.[42][46][47][48]